Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)
Wyeth is now a wholly owned subsidiary of Pfizer
The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost
analysis from a hospital perspective (including length of stay, treatment costs, side effect
management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10
score etc.); Efficacy of Tygacil under usual care conditions (cure rate).
A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting
To assess the efficacy and safety of Tygacil in the usual German hospital setting. The main
goals are: to assess the efficacy of Tygacil under usual care conditions (cure rate); to
assess the main side effects observed in daily medical practice (Safety of Tygacil); to
determine whether patients are optimally dosed with Tygacil (according to the label) and the
proportion of patients receiving a monotherapy versus combination therapy; to observe the
potential resistance development against Tygacil in Germany; to determine which antibiotic
agents are chosen for a combination therapy with Tygacil; to determine to which antibiotic
substance non-responders to Tygacil are switched; to assess the duration of the intravenous
therapy with Tygacil and to determine whether and which patients receive an oral antibiotic
substance after the therapy with Tygacil; to collect information on profile, comorbidities
and characteristics of patients treated with Tygacil.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.